Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
04:01pm, Wednesday, 14'th Aug 2024
PALO ALTO, Calif. , Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024.
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy
01:00pm, Wednesday, 10'th Jul 2024
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
09:25am, Thursday, 20'th Jun 2024
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
12:30pm, Friday, 14'th Jun 2024
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
04:36pm, Wednesday, 29'th May 2024
PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
01:56pm, Thursday, 16'th May 2024
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
04:01pm, Wednesday, 15'th May 2024
PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
07:32pm, Monday, 13'th May 2024
PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. KSI-501 clinical and non-clinical data high
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
01:11pm, Thursday, 04'th Apr 2024
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
01:00pm, Monday, 01'st Apr 2024
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
08:57pm, Thursday, 28'th Mar 2024
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
06:30am, Thursday, 28'th Mar 2024
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
06:15am, Tuesday, 26'th Mar 2024
PALO ALTO, Calif. , March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
12:56pm, Thursday, 01'st Feb 2024
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
